Preclinical and Clinical Translation of Immunomodulatory Role of Mesenchymal Stem Cells in Cancer Therapy Era.

Authors

Yutao Wu

Published in

Tissue engineering and regenerative medicine. Aug 14, 2026. Epub Aug 14, 2026.

Abstract

Mesenchymal stem cells (MSCs) are multipotent stromal cells with dual regenerative and immunomodulatory properties that have attracted growing attention in cancer therapy. Their inherent tumor-homing ability enables localized delivery of therapeutic agents, while their capacity to regulate both innate and adaptive immunity positions MSCs at the interface of stromal biology and cancer immunotherapy. However, MSC functions are highly context-dependent and vary across tumor types.
This review summarizes preclinical and clinical evidence on the immunomodulatory roles of MSCs in cancer. Experimental studies and early-phase clinical trials involving unmodified, preconditioned, and genetically engineered MSCs, as well as MSC-derived extracellular vesicles, were evaluated.
Unmodified MSCs often promote immune evasion by expanding regulatory T cells, expressing checkpoint ligands, and secreting immunosuppressive and metabolic mediators, such as IDO, nitric oxide, and PGE₂. In contrast, engineered or primed MSCs can redirect immune responses toward activation, enhancing NK- and T-cell cytotoxicity and enabling targeted delivery of cytokines, oncolytic viruses, and pro-apoptotic ligands. Early clinical trials generally demonstrate safety and feasibility; however, efficacy remains variable due to heterogeneity of MSC sources, manufacturing challenges, and lack of standardized potency assays. Notably, tumor-promoting effects have been reported under specific conditions.
MSCs Represent a highly plastic and programmable platform for immune modulation in cancer. Advances in genetic engineering and extracellular vesicle-based strategies may improve therapeutic efficacy while reducing oncogenic risk.

PMID:
42601582
Bibliographic data and abstract were imported from PubMed on 15 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.